Research programme: RNA interference therapeutics - Alnylam Pharmaceuticals/Vir Biotechnology

Drug Profile

Research programme: RNA interference therapeutics - Alnylam Pharmaceuticals/Vir Biotechnology

Latest Information Update: 28 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Vir Biotechnology
  • Class Anti-infectives; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Infections

Most Recent Events

  • 07 Jan 2018 Alnylam plans to file one or more new clinical trial applications in Infections 2018
  • 19 Oct 2017 Alnylam and Vir Biotechnology enters into a license agreement for development and commercialisation of RNAi therapeutics for infectious diseases
  • 19 Oct 2017 Early research in Infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top